MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$4,086K
Free Cash flow
-$16,431K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of inve...
    • Proceeds from the issuance of co...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Purchases of investment securiti...
    • Accounts payable and other liabi...
    • Prepaid expense and other assets
    • Amortization of premiums on inve...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-17,636 -15,997 -16,997 -36,798
Depreciation
157 156 155 311
Stock-based compensation
3,924 3,435 3,590 7,524
Amortization of premiums on investment securities, net
147 512 767 1,974
Non-cash lease expense
69 -8 -7 -6
Deferred financing costs
NaN 0 0 427
Prepaid expense and other assets
287 880 -459 955
Accounts payable and other liabilities
-2,511 1,840 2,405 241
Net cash used in operating activities
-16,431 -11,966 -11,162 -31,230
Purchases of investment securities
52,589 87,624 78,075 126,080
Proceeds from maturities of investment securities
45,000 76,075 84,585 154,225
Purchases of property and equipment
0 34 0 159
Net cash (used in) provided by investing activities
-7,589 -11,583 6,510 27,986
Issuance of common stock through employee stock purchase plan
NaN 288 0 361
Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs
19,907 24,847 NaN NaN
Proceeds from the exercise of stock options
27 182 37 23
Net cash provided by financing activities
19,934 25,317 37 384
Net (decrease) increase in cash and cash equivalents
-4,086 1,768 -4,615 -2,860
Cash and cash equivalents at beginning of period
16,856 15,088 22,563 NaN
Cash and cash equivalents at end of period
12,770 16,856 15,088 NaN
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from theissuance of common stock...$19,907K Proceeds from theexercise of stock options$27K Net cash provided byfinancing activities$19,934K Net (decrease)increase in cash and cash...-$4,086K Canceled cashflow$19,934K Stock-based compensation$3,924K Depreciation$157K Non-cash lease expense$69K Proceeds from maturitiesof investment...$45,000K Net cash used inoperating activities-$16,431K Canceled cashflow$4,150K Net cash (used in)provided by investing...-$7,589K Canceled cashflow$45,000K Net loss-$17,636K Accounts payable andother liabilities-$2,511K Prepaid expense andother assets$287K Amortization of premiums oninvestment securities, net$147K Purchases of investmentsecurities$52,589K

Design Therapeutics, Inc. (DSGN)

Design Therapeutics, Inc. (DSGN)